Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer (NCT06619236)
A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Platinum Resistant Ovarian Cancer
🩺 Plain-English Summary (8th-Grade Level)
This phase 3 study will be conducted in different countries all over the world. The purpose of this study is to compare how well Rina-S works against platinum-resistant ovarian cancer compared to chemotherapy drugs that are already approved and used for platinum-resistant ovarian cancer. Treatment in this study could be Rina-S or it could be 1 of 4 indicated chemotherapy agents that are considered standard medical care. There is an equal (50:50) chance of getting Rina-S or an approved chemotherapy agent as treatment in this study. No one will know what treatment they are assigned to until the first dose. All participants will receive active drug; no one will be given placebo.
Who can join: Review the eligibility criteria below.
Location: Alaska Women's Cancer Care — Anchorage, Alaska
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (177 Sites)
Showing the first 25 of 177 sites.
- Alaska Women's Cancer Care — Anchorage, Alaska
- Arizona Center for Cancer Care (ACCC) - Biltmore — Scottsdale, Arizona
- University of Arizona Cancer Center - Research and Administration at Main Campus — Tucson, Arizona
- Providence Saint Joseph Medical Center - Roy and Patricia Disney Family Cancer Center — Burbank, California
- University of California San Diego Moores Cancer Center — La Jolla, California
- USCF Mission Bay — San Francisco, California
- Kaiser Permanente - Vallejo Medical Center — Vallejo, California
- UCHealth Cancer Care - Anschutz Medical Campus - University of Colorado Cancer Center — Aurora, Colorado
- Hartford Hospital — Hartford, Connecticut
- Yale School of Medicine — New Haven, Connecticut
- Norwalk Hospital — Norwalk, Connecticut
- SCRI - Florida Cancer Specialists - South Region Research Office — Fort Myers, Florida
- Mount Sinai Comprehensive Cancer Center — Miami Beach, Florida
- Orlando Health Cancer Institute - Downtown Orlando — Orlando, Florida
- Sarasota Memorial Hospital — Sarasota, Florida
- SCRI - Florida Cancer Specialists - West Palm Beach — West Palm Beach, Florida
- Winship Cancer Institute of Emory University — Atlanta, Georgia
- Northside Hospital Atlanta — Atlanta, Georgia
- Augusta University Georgia Cancer Center — Augusta, Georgia
- Kapi'olani Medical Center for Women and Children — Honolulu, Hawaii
- Northwest Cancer Center - Dyer — Dyer, Indiana
- University of Kansas Cancer Center — Kansas City, Kansas
- HCA Midwest Health — Overland Park, Kansas
- St. Elizabeth Healthcare - Edgewood — Edgewood, Kentucky
- Baptist Health Lexington — Lexington, Kentucky
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Platinum-resistant Ovarian Cancer
- Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1) — Phoenix, Arizona
- A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors — Little Rock, Arkansas
- A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer — El Segundo, California
- Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer — Boston, Massachusetts
- Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) — Mobile, Alabama
Explore by condition: All Platinum-resistant Ovarian Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.